Tipp

Endometrial cancer treated with levonorgestrel-releasing intrauterine device for almost three years in an elderly woman with comorbidity

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 2/2016

Autoren:: M.D. Lisbeth Anita Andreasen, M.D., Ph.D Sofie Leisby Antonsen, M.D., Ph.D Annette Settnes

Summary

In this case report we describe the treatment of a 95-year-old woman with endometrioid adenocarcinoma. She suffered from cardiovascular comorbidity and did not want surgical treatment. Instead a levonorgestrel-releasing intrauterine device (Mirena) was inserted. She had progression of the tumor but with a minimum of symptoms and side effects. At the final examination there were no signs of extra uterine disease. The levonorgestrel-releasing intrauterine device may be an acceptable alternative to surgery in severely comorbid patients, or if the patient refuses surgical treatment.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Bovicelli A, D’Andrilli G, Giordano A, De Iaco P. Conservative treatment of early endometrial cancer. J Cell Physiol. 2013;228(6):1154–8. doi:10.1002/jcp.24292. CrossRefPubMed

Ruan X, Mueck AO. Systemic progesterone therapy – oral, vaginal, injections and even transdermal? Maturitas. 2014;79(3):248–55. doi:10.1016/j.maturitas.2014.07.009. CrossRefPubMed

Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477–82. doi:10.1016/j.ygyno.2012.01.003. CrossRefPubMed

Kim MK, Seong SJ, Kim YS, et al. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer. Am J Obstet Gynecol. 2013;209(4):358.e1–358.e4. doi:10.1016/j.ajog.2013.06.031. CrossRef

Perri T, Korach J, Gotlieb WH, et al. Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved. Int J Gynecol Cancer. 2011;21(1):72–8. doi:10.1097/IGC.0b013e31820003de. CrossRefPubMed

Montz FJ, Bristow BE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002;186:651–7. CrossRefPubMed

Giannopoulos T, Butler-Manuel S, Tailor A. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol Oncol. 2004;95(3):762–4. CrossRefPubMed

Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol. 2005;97(3):924–7, Jun. CrossRefPubMed

Titel: Endometrial cancer treated with levonorgestrel-releasing intrauterine device for almost three years in an elderly woman with comorbidity
Autoren:: M.D. Lisbeth Anita Andreasen
M.D., Ph.D Sofie Leisby Antonsen
M.D., Ph.D Annette Settnes
Publikationsdatum: 01.06.2016
DOI: https://doi.org/10.1007/s12254-016-0266-4
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 2/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option

Immune checkpoint blockade in ovarian cancer

Is there room for chemotherapy in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) in the era of targeted hormone therapy?

Intravascular large B‑cell lymphoma

Immunotherapy for head and neck squamous cell carcinoma

memo—new frontiers to be reached